Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Eisai and ImFDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia

pharmafocusasiaMarch 12, 2019

Tag: Eisai , Imbrium Therapeutics , Luxembourgian

PharmaSources Customer Service